Diabetes microvascular complications—A clinical update

Chung, 2005, Aldose reductase in diabetic microvascular complications, Curr Drug Targets, 6, 475, 10.2174/1389450054021891

Rossing, 2006, Diabetic nephropathy: worldwide epidemic and effects of current treatment on natural history, Curr Diab Rep, 6, 479, 10.1007/s11892-006-0083-y

American Diabetes Association, 2010, Diagnosis and classification of diabetes mellitus, Diabetes Care, 1, S62, 10.2337/dc10-S062

American Diabetes Association, 2008, Economic costs of diabetes in the US in 2007, Diabetes Care, 3, 596, 10.2337/dc08-9017

Li, 2015, Glycemic control paradox: poor glycemic control associated with higher one-year and eight-year risks of all-cause hospitalization but lower one-year risk of hypoglycemia in patients with type 2 diabetes, Metabolism, 64, 1013, 10.1016/j.metabol.2015.05.004

Zoungas, 2012, Association of HbA1c levels with vascular complications and death in patients with type 2 diabetes: evidence of glycaemic thresholds, Diabetologia, 55, 636, 10.1007/s00125-011-2404-1

Inzucchi, 2012, Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD), Diabetologia, 55, 1577, 10.1007/s00125-012-2534-0

Zhiheng, 2004, Microvascular complications of diabetes, Endocrinol Metab Clin, 33, 1

Lin, 2010, Depression and advanced complications of diabetes. a prospective cohort study, Diabetes Care, 33, 264, 10.2337/dc09-1068

Raman, 2012, Prevalence and risk factors for diabetic microvascular complications in newly diagnosed type II diabetes mellitus, J Diabetes Complicat, 26, 123, 10.1016/j.jdiacomp.2012.02.001

Zoungas, 2014, Impact of age, age at diagnosis and duration of diabetes on the risk of macrovascular and microvascular complications and death in type 2 diabetes, Diabetologia, 57, 2465, 10.1007/s00125-014-3369-7

Krolewski, 1987, Epidemiologic approach to the etiology of type I diabetes mellitus and its complications, N Engl J Med, 317, 1390, 10.1056/NEJM198711263172206

Jerneld, 1986, Relationship of duration and onset of diabetes to prevalence of diabetic retinopathy, Am J Ophthalmol, 102, 431, 10.1016/0002-9394(86)90069-3

Zochodne, 2014, Mechanisms of diabetic neuropathy: schwann cells, 126, 401

Tesfaye, 2005, Vascular risk factors and diabetic neuropathy, N Engl J Med, 352, 341, 10.1056/NEJMoa032782

Callaghan, 2012, Diabetic neuropathy: clinical manifestations and current treatments, Lancet Neurol, 6, 521, 10.1016/S1474-4422(12)70065-0

Franco, 2011, Nonpharmacologic therapies in diabetic neuropathic pain: a review, Acta Paulista de Enfermagem, 24, 284, 10.1590/S0103-21002011000200020

Khalil, 2013, Painful diabetic neuropathy management, Int J Evid‐Based Healthcare, 11, 77, 10.1111/1744-1609.12010

Cohen, 2015, Pharmacological treatment of diabetic peripheral neuropathy, Pharmacy Ther, 40, 372

van Nooten, 2015, A systematic literature review and network meta-analysis of capsaicin 8% patch versus oral neuropathic pain medications for the treatment of painful diabetic peripheral neuropathy, Value Health, 18, A659, 10.1016/j.jval.2015.09.2388

Spallone, 2012, Management of painful diabetic neuropathy: guideline guidance or jungle?, Curr Diab Rep, 12, 403, 10.1007/s11892-012-0287-2

Saaddine, 2008, Projection of diabetic retinopathy and other major eye diseases among people with diabetes mellitus: United States, 2005–2050, Arch Ophthalmol, 126, 1740, 10.1001/archopht.126.12.1740

Franklin, 2014, Diagnosis of diabetic retinopathy by employing image processing technique to detect exudates in retinal images, IET Image Process, 8, 601, 10.1049/iet-ipr.2013.0565

Zhang, 2014, Glucocorticoids: structure, signaling and molecular mechanisms in the treatment of diabetic retinopathy and diabetic macular edema, Current Mol Med, 14, 376, 10.2174/1566524014666140128114414

UK Prospective Diabetes Study Group, 1998, Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38, BMJ, 31, 7160

Nordwall, 2015, Impact of HbA1c, followed from onset of type 1 diabetes, on the development of severe retinopathy and nephropathy: the VISS Study (Vascular Diabetic Complications in Southeast Sweden), Diabetes Care, 38, 308, 10.2337/dc14-1203

Do, 2015, Blood pressure control for diabetic retinopathy, Cochrane Database Syst Rev, CD006127

Keech, 2007, Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial, Lancet, 370, 1687, 10.1016/S0140-6736(07)61607-9

ACCORD Study Group, 2010, Effects of medical therapies on retinopathy progression in type 2 diabetes, N Engl J Med, 2010, 233, 10.1056/NEJMoa1001288

Wang, 2015, Effects of RAS inhibitors on diabetic retinopathy: a systematic review and meta-analysis, Lancet Diabetes Endocrinol, 3, 263, 10.1016/S2213-8587(14)70256-6

Abbate, 2011, Prevention and treatment of diabetic retinopathy: evidence from clinical trials and perspectives, Curr Diabetes Rev, 7, 190, 10.2174/157339911795843168

LambersHeerspink, 2015, Dapagliflozin reduces albuminuria on top of renin-angiotensin system blockade in hypertensive diabetic patients [Poster 1176-P], Diabetes, 64, A303

Zhang, 2014, Glucocorticoids: structure, signaling and molecular mechanisms in the treatment of diabetic retinopathy and diabetic macular edema, Curr Mol Med, 14, 376, 10.2174/1566524014666140128114414

Solomon, 2014, Anti-vascular endothelial growth factor for neovascular age-related macular degeneration, Cochrane Database Syst Rev, CD005139

Raczyńska, 2014, Current trends in the monitoring and treatment of diabetic retinopathy in young adults, Mediators Inflamm

Stavniichuk, 2014, Peroxynitrite and protein nitration in the pathogenesis of diabetic peripheral neuropathy, Diabetes Metab Res Rev, 30, 669, 10.1002/dmrr.2549

Hajhosseiny, 2014, Have we reached the limits for the treatment of diabetic nephropathy?, Expert Opin Investig Drugs, 23, 511, 10.1517/13543784.2014.892580

Suckling, 2010, Altered dietary salt intake for preventing and treating diabetic kidney disease, Cochrane Database Syst Rev, 12, CD006763

DCCT Research Group, 1988, Factors in development of diabetic neuropathy: baseline analysis of neuropathy in feasibility phase of Diabetes Control and Complications Trial (DCCT), Diabetes, 37, 476, 10.2337/diab.37.4.476

Fineberg, 2013, Diabetic nephropathy: diagnosis and treatment, Nat Rev Endocrinol, 9, 713, 10.1038/nrendo.2013.184

Yamout, 2016, Diabetic nephropathy: SGLT2 inhibitors might halt progression of diabetic nephropathy, Nat Rev Nephrol, 18, 583, 10.1038/nrneph.2016.109

Heerspink, 2012, Moderation of dietary sodium potentiates the renal and cardiovascular protective effects of angiotensin receptor blockers, Kidney Int, 2012, 330, 10.1038/ki.2012.74

Escobar, 2012, Emerging drug combinations to optimize renovascular protection and blood pressure goals, Int J Nephrol Renovasc Dis, 5, 69

Yorek Mark, 2014, 1

Cumbie, 2007, Current concepts in targeted therapies for the pathophysiology of diabetic microvascular complications, Vasc Health Risk Manag, 3, 823

Akileshwari, 2014, Bioflavonoid ellagic acid inhibits aldose reductase: implications for prevention of diabetic complications, J Funct Foods, 6, 374, 10.1016/j.jff.2013.11.004

Parving, 2014, Diabetic nephropathy in 2014: Improved cardiorenal prognosis in diabetic nephropathy, Nat Rev Nephrol, 11, 68, 10.1038/nrneph.2014.238

Oyenihi, 2015, Antioxidant strategies in the management of diabetic neuropathy, BioMed Res Int, 2015

Fakhrabadi, 2014, Effect of coenzyme Q10 on oxidative stress, glycemic control and inflammation in diabetic neuropathy: a double blind randomized clinical trial, Int J Vitam Nutr Res, 84, 252, 10.1024/0300-9831/a000211

House, 2010, Effect of B-vitamin therapy on progression of diabetic nephropathy: a randomized controlled trial, JAMA, 303, 1603, 10.1001/jama.2010.490

Tuttle, 2015, Effect of ruboxistaurin on albuminuria and estimated GFR in people with diabetic peripheral neuropathy: results from a randomized trial, Am J Kidney Dis, 65, 634, 10.1053/j.ajkd.2014.11.024

Papanas, 2014, Efficacy of α-lipoic acid in diabetic neuropathy, Expert Opin Pharmacother, 15, 2721, 10.1517/14656566.2014.972935

Zhou, 2016, Mesenchymal stem cells to treat diabetic neuropathy: a long and strenuous way from bench to the clinic, Cell Death Discov, 2, 16055, 10.1038/cddiscovery.2016.55

Dworkin, 2007, Pharmacologic management of neuropathic pain: evidence-based recommendations, Pain, 132, 237, 10.1016/j.pain.2007.08.033

Kim, 2012, Summary of the american diabetes association standards of medical care in diabetes 2012, J Korean Diabetes, 13, 7, 10.4093/jkd.2012.13.1.7